TY - JOUR
T1 - Consensus International sur le dépistage, le diagnostic et le traitement des patients avec troubles de l'usage de substances en cas de comorbidité avec un trouble du déficit de l'attention avec ou sans hyperactivité
AU - van Kernebeek, Michiel W.
AU - Vorspan, Florence
AU - Crunelle, Cleo L.
AU - van den Brink, Wim
AU - Dom, Geert
AU - Moggi, Franz
AU - Konstenius, Maija
AU - Franck, Johan
AU - Levin, Frances R.
AU - ICASA consensus group
AU - van de Glind, Geurt
AU - Ramos-Quiroga, Jose A.
AU - Demetrovics, Zsolt
AU - Coetzee, Corné
AU - Luderer, Mathias
AU - Schellekens, Arnt
AU - Matthys, Frieda
AU - Icick, Romain
N1 - Funding Information: Ce travail a été réalisé sous l'impulsion et la coordination du réseau ICASA. Les auteurs remercient les éditions KARGER© pour avoir autorisé la traduction de la version anglaise de ce travail. Ce travail a été conduit partiellement grâce à un financement de l'Institut de Recherche en Santé Publique (IReSP) obtenu en 2019 (RING-PHD-CASA). Publisher Copyright: © 2022 The Author(s)
PY - 2022/6
Y1 - 2022/6
N2 - Background: Attention deficit disorder with or without hyperactivity (ADHD) in adults is often associated with substance use disorders (SUD), which have an early onset and more severe development, with less effective treatment. There are no recommendations in French on the identification, diagnosis and management of these comorbid situations. Methods: We used the modified Delphi method and literature review to arrive at a consensus statement regarding the screening, diagnosis and treatment of ADHD in subjects with SUD. Results: ADHD screening tools are useful in adults with SUD. They should be used routinely for SUD, but followed by diagnostic confirmation of ADHD as soon as possible. Simultaneous and integrated treatment of ADHD and SUD, combining psychotherapy and pharmacotherapy, is recommended, including methylphenidate and amphetamines in their extended-release forms, as well as atomoxetine. High doses may be considered for patients who do not respond to standard dosing. Discussion: Diagnostic and therapeutic tools are available for the management of ADHD in the context of SUD. Pharmacological treatments are in the process of final approval in France. In subjects with ADHD, psychiatric and non-psychiatric comorbidities other than SUD are common, but should not delay multimodal management.
AB - Background: Attention deficit disorder with or without hyperactivity (ADHD) in adults is often associated with substance use disorders (SUD), which have an early onset and more severe development, with less effective treatment. There are no recommendations in French on the identification, diagnosis and management of these comorbid situations. Methods: We used the modified Delphi method and literature review to arrive at a consensus statement regarding the screening, diagnosis and treatment of ADHD in subjects with SUD. Results: ADHD screening tools are useful in adults with SUD. They should be used routinely for SUD, but followed by diagnostic confirmation of ADHD as soon as possible. Simultaneous and integrated treatment of ADHD and SUD, combining psychotherapy and pharmacotherapy, is recommended, including methylphenidate and amphetamines in their extended-release forms, as well as atomoxetine. High doses may be considered for patients who do not respond to standard dosing. Discussion: Diagnostic and therapeutic tools are available for the management of ADHD in the context of SUD. Pharmacological treatments are in the process of final approval in France. In subjects with ADHD, psychiatric and non-psychiatric comorbidities other than SUD are common, but should not delay multimodal management.
KW - Adult
KW - Attention deficit disorder with hyperactivity
KW - Comorbidity
KW - Consensus
KW - Substance use disorder
UR - http://www.scopus.com/inward/record.url?scp=85125541952&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.toxac.2022.02.001
DO - https://doi.org/10.1016/j.toxac.2022.02.001
M3 - Review article
SN - 2352-0078
VL - 34
SP - 55
EP - 67
JO - Toxicologie Analytique et Clinique
JF - Toxicologie Analytique et Clinique
IS - 2
ER -